secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076521
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M
---------------------------------------------------------------------------

- Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.
- Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.
- FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).
- First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.
- Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/0001193125-26-076521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/bdsx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer